JP2023540344A5 - - Google Patents
Info
- Publication number
- JP2023540344A5 JP2023540344A5 JP2023515057A JP2023515057A JP2023540344A5 JP 2023540344 A5 JP2023540344 A5 JP 2023540344A5 JP 2023515057 A JP2023515057 A JP 2023515057A JP 2023515057 A JP2023515057 A JP 2023515057A JP 2023540344 A5 JP2023540344 A5 JP 2023540344A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkenyl
- cycloalkyl
- haloalkyl
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063074216P | 2020-09-03 | 2020-09-03 | |
| US63/074,216 | 2020-09-03 | ||
| PCT/US2021/049021 WO2022051596A1 (en) | 2020-09-03 | 2021-09-03 | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023540344A JP2023540344A (ja) | 2023-09-22 |
| JP2023540344A5 true JP2023540344A5 (enExample) | 2024-10-02 |
| JP7840517B2 JP7840517B2 (ja) | 2026-04-06 |
Family
ID=78078375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515057A Active JP7840517B2 (ja) | 2020-09-03 | 2021-09-03 | 二環式複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12503475B2 (enExample) |
| EP (1) | EP4208444A1 (enExample) |
| JP (1) | JP7840517B2 (enExample) |
| CN (1) | CN116583502A (enExample) |
| TW (1) | TW202227397A (enExample) |
| WO (1) | WO2022051596A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016057931A1 (en) | 2014-10-10 | 2016-04-14 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| KR20260083444A (ko) | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| US12503475B2 (en) | 2020-09-03 | 2025-12-23 | Centessa Pharmaceuticals (Uk) Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| WO2022207935A1 (en) | 2021-04-02 | 2022-10-06 | Orexia Therapeutics Limited | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists |
| JP7833486B2 (ja) | 2021-05-26 | 2026-03-19 | アルカーメス，インコーポレイテッド | 置換されるカルバメート大環状化合物および関連のある治療方法 |
| CN119156375A (zh) * | 2022-03-01 | 2024-12-17 | 森特萨制药(英国)有限公司 | 双环杂环衍生物和相关用途 |
| CN115124410B (zh) * | 2022-08-13 | 2024-06-04 | 上海珂华生物科技有限公司 | 一种2-氟-4-羟基苯甲醛的制备方法 |
| TW202432109A (zh) | 2022-10-31 | 2024-08-16 | 日商武田藥品工業股份有限公司 | 食慾素２型受體促效劑之給藥 |
| JPWO2024128305A1 (enExample) | 2022-12-16 | 2024-06-20 | ||
| TW202502342A (zh) | 2023-06-02 | 2025-01-16 | 日商武田藥品工業股份有限公司 | 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途 |
| CN122374291A (zh) | 2023-12-12 | 2026-07-10 | 爱杜西亚药品有限公司 | 作为食欲素受体调节剂的芳基砜及砜酮衍生物 |
| WO2025132542A1 (en) | 2023-12-19 | 2025-06-26 | Idorsia Pharmaceuticals Ltd | Macrocyclic orexin agonists |
| WO2025137359A1 (en) * | 2023-12-20 | 2025-06-26 | Eisai R&D Management Co., Ltd. | Assay methods to identify a disease |
| GB202404750D0 (en) | 2024-04-03 | 2024-05-15 | Bial Portela & Ca Sa | Orexin receptor agonists |
| WO2025229493A1 (en) | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
| WO2025229495A1 (en) * | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| KR20260012686A (ko) * | 2024-07-18 | 2026-01-27 | (주)셀트리온 | 신규한 오렉신 2 수용체 작용제 및 이의 용도 |
| WO2026114912A1 (en) | 2024-11-27 | 2026-06-04 | H. Lundbeck A/S | Orexin 2 receptor agonists |
| WO2026114911A1 (en) | 2024-11-27 | 2026-06-04 | H. Lundbeck A/S | Orexin 2 receptor agonists |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| WO2008076415A1 (en) | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
| CA2684169C (en) | 2007-04-12 | 2012-06-19 | Joyant Pharmaceuticals, Inc. | Smac mimetic dimers and trimers useful as anti-cancer agents |
| US8030307B2 (en) | 2007-11-29 | 2011-10-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease |
| US8871794B2 (en) | 2008-06-04 | 2014-10-28 | Board Of Regents, The University Of Texas System | Small-molecule agonists for type-2 orexin receptor |
| US20100074863A1 (en) | 2008-09-17 | 2010-03-25 | Yat Sun Or | Anti-infective pyrrolidine derivatives and analogs |
| EP2275421A1 (en) * | 2009-07-15 | 2011-01-19 | Rottapharm S.p.A. | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction |
| NO2513053T3 (enExample) | 2009-12-18 | 2018-03-03 | ||
| GB201103526D0 (en) | 2011-03-02 | 2011-04-13 | Summit Corp Plc | Selective glycosidase inhibitors and uses thereof |
| EP2763532B1 (en) | 2011-10-05 | 2018-09-19 | The Board of Trustees of the Leland Stanford Junior University | Pi-kinase inhibitors with broad spectrum anti-infective activity |
| ITMI20112329A1 (it) * | 2011-12-21 | 2013-06-22 | Rottapharm Spa | Nuovi derivati spiro amminici |
| CN105916500A (zh) | 2013-11-27 | 2016-08-31 | 欧洲筛选有限公司 | 用于治疗炎性疾病的化合物、药物组合物和方法 |
| MA40404A (fr) | 2014-08-05 | 2017-06-14 | Alios Biopharma Inc | Polythérapie pour traiter un paramyxovirus |
| WO2016021629A1 (ja) | 2014-08-06 | 2016-02-11 | 塩野義製薬株式会社 | ＴｒｋＡ阻害活性を有する複素環および炭素環誘導体 |
| SG11201806429PA (en) | 2016-02-04 | 2018-08-30 | Takeda Pharmaceuticals Co | Substituted piperidine compound and use thereof |
| JP7012703B2 (ja) | 2017-03-08 | 2022-02-14 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| JP6957598B2 (ja) | 2017-03-08 | 2021-11-02 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| US10428023B2 (en) * | 2017-08-03 | 2019-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| WO2019027069A1 (ko) * | 2017-08-03 | 2019-02-07 | (주)상아프론테크 | 연료전지 전해질 강화막 및 이의 제조방법 |
| EP3816154B1 (en) | 2018-06-29 | 2025-04-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| JP7408569B2 (ja) | 2018-12-12 | 2024-01-05 | 武田薬品工業株式会社 | 複素環化合物 |
| JP7379374B2 (ja) | 2018-12-12 | 2023-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
| PE20211700A1 (es) * | 2019-01-31 | 2021-09-01 | Takeda Pharmaceuticals Co | Compuesto heterociclico y su uso |
| US11098029B2 (en) | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| JP2022547604A (ja) | 2019-09-13 | 2022-11-14 | 武田薬品工業株式会社 | 過度の眠気の治療のためのオレキシン２受容体アゴニストの使用 |
| WO2021048822A1 (en) | 2019-09-13 | 2021-03-18 | Takeda Pharmaceutical Company Limited | Tak-925 for use in treating narcolepsy |
| JPWO2021065893A1 (enExample) | 2019-09-30 | 2021-04-08 | ||
| KR20260083444A (ko) | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| PE20221730A1 (es) | 2019-11-27 | 2022-11-07 | Sumitomo Pharma Co Ltd | Derivado de cicloalquilurea |
| US20210200298A1 (en) | 2019-12-30 | 2021-07-01 | Advanced Micro Devices, Inc. | Long-idle state system and method |
| US12503475B2 (en) | 2020-09-03 | 2025-12-23 | Centessa Pharmaceuticals (Uk) Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| CN116635393A (zh) | 2020-09-03 | 2023-08-22 | 欧瑞夏治疗有限公司 | 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途 |
| WO2022207935A1 (en) | 2021-04-02 | 2022-10-06 | Orexia Therapeutics Limited | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists |
| WO2023017180A1 (en) | 2021-08-13 | 2023-02-16 | Orexia Therapeutics Limited | Peptide derivatives and related uses as orexin agonists |
| CN119156375A (zh) | 2022-03-01 | 2024-12-17 | 森特萨制药(英国)有限公司 | 双环杂环衍生物和相关用途 |
| WO2023167925A1 (en) | 2022-03-01 | 2023-09-07 | Orexia Therapeutics Limited | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses |
-
2021
- 2021-09-03 US US18/024,216 patent/US12503475B2/en active Active
- 2021-09-03 CN CN202180074263.5A patent/CN116583502A/zh active Pending
- 2021-09-03 JP JP2023515057A patent/JP7840517B2/ja active Active
- 2021-09-03 EP EP21786660.7A patent/EP4208444A1/en active Pending
- 2021-09-03 TW TW110132883A patent/TW202227397A/zh unknown
- 2021-09-03 WO PCT/US2021/049021 patent/WO2022051596A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023540350A5 (enExample) | ||
| JP2021534124A5 (enExample) | ||
| JP2023527575A5 (enExample) | ||
| KR101976218B1 (ko) | 4-히드록시부티르산 중수소화 유사체 | |
| JP2011509309A5 (enExample) | ||
| JP2021514001A5 (enExample) | ||
| JP2021529812A5 (enExample) | ||
| JP2013510883A5 (enExample) | ||
| JP2005508349A5 (enExample) | ||
| JP2025163128A5 (enExample) | ||
| JP2009507909A5 (enExample) | ||
| JP2009530248A5 (enExample) | ||
| RU2007124187A (ru) | Производные фенэтаноламина для лечения респираторных заболеваний | |
| JP2024520654A5 (enExample) | ||
| JP2005514398A5 (enExample) | ||
| JP2025507852A5 (enExample) | ||
| JP2013520473A5 (enExample) | ||
| JP2011527686A5 (enExample) | ||
| JP6261011B2 (ja) | 眼疾患処置薬 | |
| JP2013545823A5 (enExample) | ||
| JP2013542267A5 (enExample) | ||
| JP2013510884A5 (enExample) | ||
| JP2005539045A5 (enExample) | ||
| JP2009538910A5 (enExample) | ||
| ES2548258T3 (es) | Compuestos de oxadiazol sustituidos y su uso como agonistas de S1P1 |